Saturday, October 6, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall
Tracks: Pediatric ID, Epidemiology and Infection Control, Adult ID
Presentations:
Multicenter Evaluation of Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah Jorgensen, PharmD, BCPS, AAHIVP;
Trang D. Trinh, PharmD, MPH;
Evan J. Zasowski, PharmD, MPH;
Abdalhamid M. Lagnf, MPH;
Sahil Bhatia, B.S.;
Samuel Simon, PharmD;
Sandy Estrada, Pharm.D., BCPS (AQ-ID);
Joshua Rosenberg, MD;
Molly Steed, PharmD;
Susan L Davis, PharmD;
Michael J. Rybak, PharmD, MPH, PhD
Healthcare Resource Utilization for High-Risk Patients Treated with Dalbavancin in Physician Office Infusion Centers (POICs)
Quyen Luu, MD;
Barry Statner, MD, FRCPC, FIDSA;
Robin H. Dretler, MD, FIDSA;
H. Barry Baker, MD, FACP;
Brian S. Metzger, MD, MPH;
Thomas C. Hardin, PharmD;
Claudia P. Schroeder, PharmD, PhD;
Lucinda J. Van Anglen, PharmD
Ceftolozane/tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Resistance
Vidmantas Petraitis, MD;
Ruta Petraitiene, MD;
Ethan Naing, MD;
Thein Aung, MD;
Wai Phyo Thi, MD;
Povilas Kavaliauskas, BS;
C. Andrew DeRyke, PharmD;
Darren L Culshaw, PharmD;
Luzelena Caro, PhD;
Michael J. Satlin, MD, MS;
Thomas J. Walsh, MD, PhD
Multidrug-Resistant Gram-Negative Infections Treated with Ceftolozane-Tazobactam: Impact of Delayed Initiation
Sarah Jorgensen, PharmD, BCPS, AAHIVP;
Trang D. Trinh, PharmD, MPH;
Evan J. Zasowski, PharmD, MPH;
Abdalhamid M. Lagnf, MPH;
Sahil Bhatia, B.S.;
Samuel Simon, PharmD;
Sandy Estrada, Pharm.D., BCPS (AQ-ID);
Joshua Rosenberg, MD;
Molly Steed, PharmD;
Susan L Davis, PharmD;
Michael J. Rybak, PharmD, MPH, PhD
Ceftazidime-Avibactam in Combination with Fosfomycin: A Novel Therapeutic Strategy against Multidrug Resistant Pseudomonas aeruginosa
Krisztina M. Papp-Wallace, PhD;
Elise T. Zeiser, BS, MPH;
Scott A. Becka, BS;
Steven T. Park, MS;
Marisa L. Winkler, MD/PhD;
Kevin Nguyen, BS;
Indresh Singh, MS;
Granger Sutton, PhD;
Derrick E. Fouts, PhD;
Evelyn J. Ellis-Grosse, PhD;
George L. Drusano, MD;
David S. Perlin, PhD;
Robert A. Bonomo, MD
Efficacy of Lefamulin (LEF) Versus (vs) Moxifloxacin (MOX) Against Common Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Results from the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
Thomas File, MD;
Lisa Goldberg, MS;
Susanne Paukner, PhD;
Anita Das, PhD;
Steven P. Gelone, PharmD;
John Saviski, MS;
Carolyn Sweeney, BS;
Elyse Seltzer, MD;
George H. Talbot, MD;
Leanne B. Gasink, MD
Different Clostridioides difficile Ribotypes among Patients with Colonization, Initial Clinical Disease and Recurrent Clinical Disease
Kevin Khoury, MD;
Eugene Yen, MD;
Jennifer Grant, MD;
Se Hyuk Park, MS;
Talent Thaparee, MD;
Donna Schora, MT(ASCP);
Becky Smith, MD;
Kamaljit Singh, MD;
Sanchita Das, MD
Mechanism-based-susceptibility testing (MBST) using disc diffusion assays (DDA) to Guide Treatment of Multidrug- and Extensively Drug Resistant Pseudomonas aeruginosa (MDR-XDR-Pa) in a Cystic Fibrosis (CF) Lung Transplant Recipient; are we ready for combination therapy vs. MDR-XDR-Pa?
Lilian M. Abbo, MD;
Mohamad Yasmin, MD;
Steven H. Marshall, MS;
Federico Perez, MD, MS;
Mónica Corzo-Pedrosa, MD;
Jose F. Camargo, MD;
Jacques Simkins, MD;
Laura Aragon, PharmD, BCPS-AQ ID;
Shweta Anjan, MD;
Michele I Morris, MD, FIDSA, FAST;
Nicolas Brozzi, MD;
Mathias Loebe, MD;
Jesse Fulmer, MD;
Neeraj Sinha, MD;
Octavio Martinez, PhD;
Armando Perez-Cardona, BS;
Andrew Colin, MD;
Christina Cloke, MD;
Robert A. Bonomo, MD
Fosfomycin Resistance among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
Mary Snayd, MD;
Vivian Leung, MD;
Meghan Maloney, MPH;
Amanda Durante, PhD, MSc;
Bobbie Macierowski, MS;
Diane Noel, MT;
Anthony Muyombwe, PhD;
Jafar Razeq, PhD;
David Banach, MD, MPH, MS
Comparing Predictive Performance of INCREMENT Scores on Mortality Among Patients with Carbapenem-Non-Susceptible (CNS) Klebsiella pneumoniae (Kp) and Enterobacter cloacae Complex (Ecc) Bloodstream Infections (BSI) in the Veterans Health Administration (VHA)
Nadim G. El Chakhtoura, MD, MPH;
Brigid Wilson, PhD;
Belen Gutíerrez-Gutíerrez, MD, PhD;
Federico Perez, MD, MS;
Elie Saade, MD, MPH;
Curtis J. Donskey, MD;
Jesus Rodriguez-Bano, MD;
Robert A. Bonomo, MD
Utilization Practices of Ceftazidime-avibactam at Academic Medical Centers in the United States
Jeffrey R. Strich, MD;
Emily Ricotta, PhD, ScM;
Yi Ling Lai, MPH;
Samuel Hohmann, PhD;
Sadia Hussain, MD;
Chanu Rhee, MD, MPH;
Michael Klompas, MD, MPH, FRCPC, FIDSA;
Tara N. Palmore, M.D.;
John H. Powers III, MD;
John P. Dekker, M.D., Ph.D.;
Jennifer Adjemian, PhD;
Robert L. Danner, MD;
Sameer S. Kadri, MD, MS
Beta-Lactam Therapy for Potential AmpC-Producing Organisms: A Cohort Study and an Updated Systematic Review and Meta-analysis
Matthew P. Cheng, MD;
Robyn Lee, PhD;
Alexandre P. Cheng, BSc;
Samuel De L'Étoile-Morel, MD;
Koray Demir, MDCM Candidate;
Cedric Yansouni, MD;
Patrick Harris, MBBS FRACP FRCPA;
Emily Mcdonald, MDCM, MSc;
Todd C. Lee, MD, MPH
Risk factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012-2017
Thomas Fear, MD;
Karen Green, MSc, RN;
Agron Plevneshi, BSc;
Jeff Li, BSc;
Wallis Rudnick, MSc;
Sarah Nayani, PhD;
Allison McGeer, MD, MSc
"Real World" Treatment of Multi-drug Resistant (MDR) or Extensively-drug Resistant (XDR) P. aeruginosa Infections with Ceftolozane/Tazobactam (C/T) versus a Polymyxin or Aminoglycoside (Poly/AG) based regimen: A Multicenter Comparative Effectiveness Study
Jason M. Pogue, PharmD, BCPS-AQ ID;
Keith S. Kaye, MD, MPH;
Michael Veve, PharmD;
Anthony Gerlach, PharmD;
Twisha S. Patel, PharmD, BCPS;
Susan L Davis, PharmD;
Eugene Chaung, MD;
Amy Ray, MD, MPH;
Laura Puzniak, PhD, MPH;
Robert A. Bonomo, MD;
Federico Perez, MD, MS
Drug-Induced Liver Injury (DILI) in a National Cohort of Hospitalized Patients treated with Aztreonam and Ceftazidime
Elie Saade, MD, MPH;
Brigid Wilson, PhD;
Nadim G. El Chakhtoura, MD, MPH;
Roberto Viau, MD;
Federico Perez, MD, MS;
Thomas Lodise, PharmD, PhD;
Robert a. Bonomo, MD
Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017
Amanda Durante, PhD, MSc;
Meghan Maloney, MPH;
Vivian Leung, MD;
Bobbie Macierowski, MS;
Diane Noel, MT;
Jafar Razeq, PhD;
David Banach, MD, MPH, MS
The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of Clinical Evidence.
Paraskevi C. Fragkou, MD, MSc;
Garyfallia Poulakou, MD, PhD;
Myrto Blizou, MD;
Andromachi Blizou, MD;
Dimitrios K. Matthaiou, MD, MBA, PhD;
Sotirios Tsiodras, MD, MSc, PhD, FIDSA
Efficacy of Cefoxitin for the treatment of urinary tract infection (UTI) due to ESBL-producing E. coli and K. pneumoniae isolates
Olivia Senard, MD;
Frederique Bouchand, PharmD;
Laurene Deconinck, MD;
Morgan Matt, MD;
Lesly Fellous, PharmD;
Martin Rottman, MD, PhD;
Christian Perronne, MD, PhD;
Aurelien Dinh, MD;
Benjamin Davido, MD, MS
Appropriateness of Empiric Extended-Infusion Piperacillin/Tazobactam in the Intensive Care Unit
Kendall Tucker, PharmD;
Molly Benning, BS;
Keenan Ryan, PharmD, PhC;
Carla Walraven, PharmD, MS;
Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP
Review of Linezolid (LZD) Use and Onset of Toxicity in 4 Belgian Hospital Centers: a Retrospective Study
Helene Thirot, PharmD;
Caroline Briquet, PharmD;
Frédéric Frippiat, MD;
Frederique Jacobs, MD;
Xavier Holemans, MD;
Paul Tulkens, MD;
Anne Spinewine, Pharm, PhD;
Francoise Van Bambeke, PharmD, PhD
Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections due to Serratia, Citrobacter or Enterobacter
James Go, PharmD;
Katie L. Wallace, PharmD, BCPS;
David S. Burgess, PharmD, FCCP, FIDP;
Donna R. Burgess, RPh;
Sarah Cotner, PharmD, BCPS;
Vaneet Arora, MD, MPH, D(ABMM)
Colistin usage, Do we need to worry about its toxicity among children with cancer?
Reham Khedr, MD, PhD;
Naglaa Ahmed, PharmB, MSc;
Mervat Alenany, PhD;
Hanan Elabhar, PhD;
Hala Salem, PhD;
Hanafy Hafez, MD, PhD
Outcomes of Patients with Vancomycin-resistant Enterococcus Blood Stream Infections (BSI) Treated with Daptomycin
Luis A Shimose, MD;
Maria X Bueno Rios, MD;
Vasilios Athans, PharmD, BCPS;
Stephanie Bass, PharmD;
Manshi Li, MS;
Xiaofeng Wang, PhD;
Joshua Otiso, MPH, MLS (ASCP);
Abhijit Duggal, MD, MPH, MSc;
Sandra S. Richter, MD;
Christopher Kovacs, MD
Incidence of Daptomycin Toxicity Among Patients with Vancomycin-resistant Enterococcus Blood Stream Infections
Maria X Bueno Rios, MD;
Luis A Shimose, MD;
Vasilios Athans, PharmD, BCPS;
Stephanie Bass, PharmD;
Joshua Otiso, MPH, MLS (ASCP);
Manshi Li, MS;
Xiaofeng Wang, PhD;
Abhijit Duggal, MD, MPH, MSc;
Sandra S. Richter, MD;
Christopher Kovacs, MD
Efficacy and Tolerability of Linezolid for Treatment of Infectious Spondylitis
Jongtak Jung, M.D;
Eunyoung Lee, M.D.;
Kyoung-Ho Song, M.D., Ph.D.;
Pyeong Gyun Choe, M.D.;
Nam Joong Kim, M.D., Ph.D.;
Eu Suk Kim, M.D., Ph.D.;
Ji Hwan Bang, M.D.;
Sang Won Park, M.D., Ph.D.;
Hong Bin Kim, M.D., Ph.D.;
Wan Beom Park, M.D., Ph.D;
Myoung-Don Oh, M.D., Ph.D.
Clinical spectrum and outcomes of Colistin-resistant Carbapenem resistant Enterobacteriaceae
Sara Ahmed, MBBS, FCPS Medicine;
Syed Faisal Mahmood, MBBS, DABIM, DABIM (ID);
Fatima Sharif, MBBS;
Mariam Aijaz, MBBS;
Safia Awan, MSc Statistics;
Bushra Jamil, MBBS, FRCP, FACP
Validation of In vitro Activity of Aminoglycosides Against Recently Isolated Helicobacter pylori for Commercialization of Gentamicin-intercalated Smectite Hybrid as A New Therapeutic Agent
Kyoung Hwa Lee, MD;
Soon Young Park, MS;
Seul Gi Yoo, MD;
Da Eun Kwon, MD;
Su Jin Jeong, MD/PhD;
Da Hyun Jung, MD;
Jie-Hyun Kim, MD/PhD;
Seok Hoon Jeong, MD/PhD;
Il-Mo Kang, MS;
Young Goo Song, MD, PhD
Antibiotic Treatment for Carbapenem-Resistant Enterobacteriaceae (CRE) and Outcomes in Veterans with Spinal Cord Injury/Disorder (SCI/D)
Erica K. Little, PharmD;
Ursula C. Patel, PharmD, BCPS, AAHIVP;
Katie J. Suda, PharmD, M.S.;
Margaret Fitzpatrick, MD, M.S.;
Charlesnika T. Evans, PhD, MPH
CME Credits: Maximum of 0.00 hours of
AMA PRA Category 1 Credit™
